Contact: Dr. Chris Boshoff
Contact Email: Chris.firstname.lastname@example.org
(Please do not use your computer audio to listen to the webinar, please log in using the link and dial 1-650-479-3208 Access Code: 2556 233 513)
Time: 3 p.m. EST
This event is the first in a series and provides an overview of the Ultra-Rare Gene-Based Therapy (URGenT) network. URGenT supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Please contact Chris Boshoff with any questions prior to the webinar.
JOIN OR REGISTER FOR THE WEBINAR (Please do not use your computer audio to listen to the webinar, please log in using the link and dial 1-650-479-3208 Access Code 2556 233 5134).
All questions will be submitted online, but you are welcome to listen by dialing the number and access code. You can read a summary and view the webinar on our NINDS Events page.
We hope that you can join us!
Webinar Slides(pdf, 977 KB)